ANTITHROMBOTIC EFFECTS OF ARGININ-CONTAINING GLYPROLINE
(Abstract release date: 05/19/16)
EHA Library. Grigorjeva M. 06/09/16; 133112; E1563
Dr. Marina Grigorjeva
Contributions
Contributions
Abstract
Abstract: E1563
Type: Eposter Presentation
Background
It has been shown that glyproline peptides have the anticoagulant, fibrinolytic and antiplatelet action in the organism. The decrease of platelet aggregation can be enhanced by adding to the molecule of glyprolines arginine, which causes the release of NO in the bloodstream.
Aims
The aim of this study was to determine the antithrombotic effects of arginine-containing glyproline Pro-Gly-Pro-Arg (PGPR) in rats with experimental venous thrombosis.
Methods
The peptide PGPR was administered to experimental rats intranasally for 4 days in a daily dose of 1 mg/kg. Control animals similarly received saline. Then venous thrombosis (Wessler model) was simulated in rats. The degree of clot formation was assessed by weight of thrombus (mg). The state of the hemostasis system was estimated used standard methods: determination of anticoagulant activity (APTT), fibrinolytic activity on fibrin plates, ADP- induced aggregation of platelets.
Results
It is established that preliminary injection of PGPR lead to decrease of thrombus formation in experimental rats on 60%. Thrombus formation in control rats – 100%. Moreover in the blood plasma of experimental animals anticoagulant and fibrinolytic activity were increased by 21% and 30% respectively. Platelet aggregation was decreased at 25% compared with the control.
Conclusion
Thus arginine-containing glyproline Pro-Gly-Pro-Arg showed anticoagulant, fibrinolytic and antiplatelet properties. Therefore this drug had significant antithrombotic effects, and prevented the thrombus formation in the organism.
Session topic: E-poster
Keyword(s): Aggregation, Anticoagulation, Thrombosis
Type: Eposter Presentation
Background
It has been shown that glyproline peptides have the anticoagulant, fibrinolytic and antiplatelet action in the organism. The decrease of platelet aggregation can be enhanced by adding to the molecule of glyprolines arginine, which causes the release of NO in the bloodstream.
Aims
The aim of this study was to determine the antithrombotic effects of arginine-containing glyproline Pro-Gly-Pro-Arg (PGPR) in rats with experimental venous thrombosis.
Methods
The peptide PGPR was administered to experimental rats intranasally for 4 days in a daily dose of 1 mg/kg. Control animals similarly received saline. Then venous thrombosis (Wessler model) was simulated in rats. The degree of clot formation was assessed by weight of thrombus (mg). The state of the hemostasis system was estimated used standard methods: determination of anticoagulant activity (APTT), fibrinolytic activity on fibrin plates, ADP- induced aggregation of platelets.
Results
It is established that preliminary injection of PGPR lead to decrease of thrombus formation in experimental rats on 60%. Thrombus formation in control rats – 100%. Moreover in the blood plasma of experimental animals anticoagulant and fibrinolytic activity were increased by 21% and 30% respectively. Platelet aggregation was decreased at 25% compared with the control.
Conclusion
Thus arginine-containing glyproline Pro-Gly-Pro-Arg showed anticoagulant, fibrinolytic and antiplatelet properties. Therefore this drug had significant antithrombotic effects, and prevented the thrombus formation in the organism.
Session topic: E-poster
Keyword(s): Aggregation, Anticoagulation, Thrombosis
Abstract: E1563
Type: Eposter Presentation
Background
It has been shown that glyproline peptides have the anticoagulant, fibrinolytic and antiplatelet action in the organism. The decrease of platelet aggregation can be enhanced by adding to the molecule of glyprolines arginine, which causes the release of NO in the bloodstream.
Aims
The aim of this study was to determine the antithrombotic effects of arginine-containing glyproline Pro-Gly-Pro-Arg (PGPR) in rats with experimental venous thrombosis.
Methods
The peptide PGPR was administered to experimental rats intranasally for 4 days in a daily dose of 1 mg/kg. Control animals similarly received saline. Then venous thrombosis (Wessler model) was simulated in rats. The degree of clot formation was assessed by weight of thrombus (mg). The state of the hemostasis system was estimated used standard methods: determination of anticoagulant activity (APTT), fibrinolytic activity on fibrin plates, ADP- induced aggregation of platelets.
Results
It is established that preliminary injection of PGPR lead to decrease of thrombus formation in experimental rats on 60%. Thrombus formation in control rats – 100%. Moreover in the blood plasma of experimental animals anticoagulant and fibrinolytic activity were increased by 21% and 30% respectively. Platelet aggregation was decreased at 25% compared with the control.
Conclusion
Thus arginine-containing glyproline Pro-Gly-Pro-Arg showed anticoagulant, fibrinolytic and antiplatelet properties. Therefore this drug had significant antithrombotic effects, and prevented the thrombus formation in the organism.
Session topic: E-poster
Keyword(s): Aggregation, Anticoagulation, Thrombosis
Type: Eposter Presentation
Background
It has been shown that glyproline peptides have the anticoagulant, fibrinolytic and antiplatelet action in the organism. The decrease of platelet aggregation can be enhanced by adding to the molecule of glyprolines arginine, which causes the release of NO in the bloodstream.
Aims
The aim of this study was to determine the antithrombotic effects of arginine-containing glyproline Pro-Gly-Pro-Arg (PGPR) in rats with experimental venous thrombosis.
Methods
The peptide PGPR was administered to experimental rats intranasally for 4 days in a daily dose of 1 mg/kg. Control animals similarly received saline. Then venous thrombosis (Wessler model) was simulated in rats. The degree of clot formation was assessed by weight of thrombus (mg). The state of the hemostasis system was estimated used standard methods: determination of anticoagulant activity (APTT), fibrinolytic activity on fibrin plates, ADP- induced aggregation of platelets.
Results
It is established that preliminary injection of PGPR lead to decrease of thrombus formation in experimental rats on 60%. Thrombus formation in control rats – 100%. Moreover in the blood plasma of experimental animals anticoagulant and fibrinolytic activity were increased by 21% and 30% respectively. Platelet aggregation was decreased at 25% compared with the control.
Conclusion
Thus arginine-containing glyproline Pro-Gly-Pro-Arg showed anticoagulant, fibrinolytic and antiplatelet properties. Therefore this drug had significant antithrombotic effects, and prevented the thrombus formation in the organism.
Session topic: E-poster
Keyword(s): Aggregation, Anticoagulation, Thrombosis
{{ help_message }}
{{filter}}